Ray Rubela, Mahmood Arhum, Chaudhry Raheel, Masmoum Mohd Diya, Talha Muhammad, Siddiqui Fahad I, Ullah Imdad
Bankura Sammilani Medical College, Bankura, India.
Henry Ford Health System, Detroit, MI 48202, USA.
Curr Cardiol Rev. 2025;21(5):29-41. doi: 10.2174/011573403X345749250122092324.
INTRODUCTION: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search. METHODS: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total. RESULTS: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors. CONCLUSION: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.
引言：降低动脉粥样硬化性心血管疾病风险是降脂治疗（动脉粥样硬化性心血管疾病）的目标。人们普遍认为低密度脂蛋白（LDL）是动脉粥样硬化性心血管疾病的主要病因。使用了几个在线数据库和搜索引擎，如PubMed和Cochrane图书馆，进行全面检索。 方法：本研究纳入了评估前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对心血管事件影响的随机对照试验（RCT）。使用RevMan 5.4软件进行荟萃分析。该分析总共纳入了9项随机对照试验。 结果：对纳入研究的荟萃分析表明，使用PCSK9抑制剂后，总胆固醇、低密度脂蛋白和甘油三酯水平降低，高密度脂蛋白水平升高，高密度脂蛋白是有益胆固醇。使用PCSK9抑制剂后，大多数主要不良心血管事件（MACE）减少。 结论：总之，依泽替米贝作为一种添加到他汀类药物治疗中的PCSK9抑制剂，即使他汀类药物已经显著降低主要不良心血管事件（MACE）和死亡率，仍能进一步降低MACE风险，且不影响全因死亡率。
Cochrane Database Syst Rev. 2017-4-28
Int J Environ Res Public Health. 2022-12-16
Vasc Health Risk Manag. 2023
Cardiovasc Diabetol. 2022-6-15
Zotero 插件